Posters
Correction of high myopia: how, when and why
Poster Details
First Author: M. Dvali GEORGIA
Co Author(s): B. Sirbiladze N. Tsintsadze
Abstract Details
Purpose:
as well as expedience correction of high myopia is evaluation the efficacy, safety and predictability of high myopia correction.
Setting:
Tbilisi State Medical University; Eye Clinic 'Akhali Mzera'
Methods:
To achieve these purposes we referred to following methods: Lasik Tissue Saving (TS), posterior chamber IOL phakic implantation (ICL, STAAR), Bioptics (phakic IOL implantation + LASIK), and clear lens extraction. In the beginning we preferred to use to implant AC IOL (Phakic6, OII) as an only procedure or within Bioptic method. With appearance of the new models of phakic IOLs, enabling to correct spherical & astigmatic component together, we used ICLV4 with optimized profile regarding the contact with anterior surface of the lens. All the patients were undergone the thorough observation of retinal periphery and laser photocoagulation if necessary.
Results:
The findings showed that all methods resulted in high functional results, almost identical of planned ones. Individual approach is needed to choose the optimum. In younger people, we preferred phakic IOLs implantation to keep accommodative ability. With ACD < 3 mm implantation of AC phakic IOL is not recommended. ICL TORIC as well Bioptic method can be used for correction of high myopia with astigmatism, though the latter needs two stages of surgical interference. In individuals with high myopia, “thick” cornea, narrow AC (also taking into consideration patients’ desire and financial matter) we preferred Lasik TS.
Conclusions:
The further researches and investigations in the field of eye structure (endothelium, iris, the capsule of the lens, trabecular meshwork and cetera) after endoocular correction can reveal another advantages & disadvantages, stability of the results and can create another considerations for assessment of efficacy as well safety and predictability as the main purpose of refractive surgery procedures.
Financial Disclosure:
NONE